Atsena Therapeutics Receives FDA RPD Designation for X-Linked Retinoschisis Gene Therapy Candidate
On August 14, 2024, Atsena Therapeutics (New Haven, CT, USA), a gene therapy company focused on combating inherited blindness, announced…
From Stem Cells, Gene Editing, to AI and Animal Perception–The ‘Back-End’ of Vision Research Takes Center Stage at ARVO 2024: Day One Round-Up
It’s on here in Seattle for ARVO 2024, and in truly momentous fashion. Thousands of delegates from around the world…
popular posts
latest posts
